HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approa...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-01, Vol.14 (3), p.512 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 512 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Bueno Muiño, Coralia Martín, Miguel Del Monte-Millán, María García-Saénz, José Ángel López-Tarruella, Sara |
| description | Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed. |
| doi_str_mv | 10.3390/cancers14030512 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8833556</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2627530616</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-c5284a05bde31476f87ce5e3b703f62ec0b1a644800b8454e6beee24041a6ff33</originalsourceid><addsrcrecordid>eNpdkctLAzEQxoMoKurZmwS8CLKad7YeBK31AYLi4xyy6WyNbJOa7Ar97936oprLhG9-8zHDh9AuJUecD8ixs8FBylQQTiRlK2iTEc0KpQZidem_gXZyfiX945xqpdfRBpdUllqXm2h8PXpgh_g8gc0tHn464lF2trGtjwHbMMYXUCwpT8nbpteyn4QTfB9bCO1CeYgN4Fjjm9AmH7J3-LGr2vnMh8k2Wqttk2Hnu26h58vR0_C6uL27uhme3RZOMNoWTrJSWCKrMXAqtKpL7UACrzThtWLgSEWtEqIkpCqFFKAqAGCCiF6ua8630OmX76yrpjB2_WbJNmaW_NSmuYnWm7-d4F_MJL6bsuRcStUbHHwbpPjWQW7N1GcHTWMDxC4bptiAyAGlrEf3_6GvsUuhP29BacmJogvD4y_KpZhzgvp3GUrMIkTzL8R-Ym_5hl_-JzL-AVWEmKw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627530616</pqid></control><display><type>article</type><title>HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Bueno Muiño, Coralia ; Martín, Miguel ; Del Monte-Millán, María ; García-Saénz, José Ángel ; López-Tarruella, Sara</creator><creatorcontrib>Bueno Muiño, Coralia ; Martín, Miguel ; Del Monte-Millán, María ; García-Saénz, José Ángel ; López-Tarruella, Sara</creatorcontrib><description>Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14030512</identifier><identifier>PMID: 35158778</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biology ; Breast cancer ; Chemotherapy ; Clinical medicine ; Clinical trials ; Design ; Drugs ; ErbB-2 protein ; Gene expression ; Kinases ; Medical prognosis ; Mortality ; Patients ; Protein expression ; Review ; Tumors ; Variables</subject><ispartof>Cancers, 2022-01, Vol.14 (3), p.512</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-c5284a05bde31476f87ce5e3b703f62ec0b1a644800b8454e6beee24041a6ff33</citedby><cites>FETCH-LOGICAL-c421t-c5284a05bde31476f87ce5e3b703f62ec0b1a644800b8454e6beee24041a6ff33</cites><orcidid>0000-0001-6880-0301 ; 0000-0002-2606-9538 ; 0000-0001-9237-3231</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833556/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833556/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35158778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bueno Muiño, Coralia</creatorcontrib><creatorcontrib>Martín, Miguel</creatorcontrib><creatorcontrib>Del Monte-Millán, María</creatorcontrib><creatorcontrib>García-Saénz, José Ángel</creatorcontrib><creatorcontrib>López-Tarruella, Sara</creatorcontrib><title>HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed.</description><subject>Biology</subject><subject>Breast cancer</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Design</subject><subject>Drugs</subject><subject>ErbB-2 protein</subject><subject>Gene expression</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Patients</subject><subject>Protein expression</subject><subject>Review</subject><subject>Tumors</subject><subject>Variables</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkctLAzEQxoMoKurZmwS8CLKad7YeBK31AYLi4xyy6WyNbJOa7Ar97936oprLhG9-8zHDh9AuJUecD8ixs8FBylQQTiRlK2iTEc0KpQZidem_gXZyfiX945xqpdfRBpdUllqXm2h8PXpgh_g8gc0tHn464lF2trGtjwHbMMYXUCwpT8nbpteyn4QTfB9bCO1CeYgN4Fjjm9AmH7J3-LGr2vnMh8k2Wqttk2Hnu26h58vR0_C6uL27uhme3RZOMNoWTrJSWCKrMXAqtKpL7UACrzThtWLgSEWtEqIkpCqFFKAqAGCCiF6ua8630OmX76yrpjB2_WbJNmaW_NSmuYnWm7-d4F_MJL6bsuRcStUbHHwbpPjWQW7N1GcHTWMDxC4bptiAyAGlrEf3_6GvsUuhP29BacmJogvD4y_KpZhzgvp3GUrMIkTzL8R-Ym_5hl_-JzL-AVWEmKw</recordid><startdate>20220120</startdate><enddate>20220120</enddate><creator>Bueno Muiño, Coralia</creator><creator>Martín, Miguel</creator><creator>Del Monte-Millán, María</creator><creator>García-Saénz, José Ángel</creator><creator>López-Tarruella, Sara</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6880-0301</orcidid><orcidid>https://orcid.org/0000-0002-2606-9538</orcidid><orcidid>https://orcid.org/0000-0001-9237-3231</orcidid></search><sort><creationdate>20220120</creationdate><title>HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping</title><author>Bueno Muiño, Coralia ; Martín, Miguel ; Del Monte-Millán, María ; García-Saénz, José Ángel ; López-Tarruella, Sara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-c5284a05bde31476f87ce5e3b703f62ec0b1a644800b8454e6beee24041a6ff33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biology</topic><topic>Breast cancer</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Design</topic><topic>Drugs</topic><topic>ErbB-2 protein</topic><topic>Gene expression</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Patients</topic><topic>Protein expression</topic><topic>Review</topic><topic>Tumors</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bueno Muiño, Coralia</creatorcontrib><creatorcontrib>Martín, Miguel</creatorcontrib><creatorcontrib>Del Monte-Millán, María</creatorcontrib><creatorcontrib>García-Saénz, José Ángel</creatorcontrib><creatorcontrib>López-Tarruella, Sara</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bueno Muiño, Coralia</au><au>Martín, Miguel</au><au>Del Monte-Millán, María</au><au>García-Saénz, José Ángel</au><au>López-Tarruella, Sara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-01-20</date><risdate>2022</risdate><volume>14</volume><issue>3</issue><spage>512</spage><pages>512-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Long-term outcomes in breast cancer patients differ based on the molecular subtype, with HER2-E being the most aggressive one. Advances in clinical practice have dramatically shifted HER2+ breast cancer prognosis. Risk adapted strategies to individualize therapies are necessary. De-escalation approaches have been encouraged based on the risks of clinical-pathological factors. Molecular gene subtyping could further accurately define HER2 addicted tumours that are sensitive to anti-HER2 therapies, thus sparing unnecessary treatments. The transition from immunochemistry to molecular profiling in HER2+ breast cancer is discussed.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35158778</pmid><doi>10.3390/cancers14030512</doi><orcidid>https://orcid.org/0000-0001-6880-0301</orcidid><orcidid>https://orcid.org/0000-0002-2606-9538</orcidid><orcidid>https://orcid.org/0000-0001-9237-3231</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-01, Vol.14 (3), p.512 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8833556 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biology Breast cancer Chemotherapy Clinical medicine Clinical trials Design Drugs ErbB-2 protein Gene expression Kinases Medical prognosis Mortality Patients Protein expression Review Tumors Variables |
| title | HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A17%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER2+%20Breast%20Cancer%20Escalation%20and%20De-Escalation%20Trial%20Design:%20Potential%20Role%20of%20Intrinsic%20Subtyping&rft.jtitle=Cancers&rft.au=Bueno%20Mui%C3%B1o,%20Coralia&rft.date=2022-01-20&rft.volume=14&rft.issue=3&rft.spage=512&rft.pages=512-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14030512&rft_dat=%3Cproquest_pubme%3E2627530616%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627530616&rft_id=info:pmid/35158778&rfr_iscdi=true |